Literature DB >> 17546492

Role of a consensus AP-2 regulatory sequence within the Epstein-Barr virus LMP1 promoter in EBNA2 mediated transactivation.

Ann Jansson1, Pegah Johansson, Weiwen Yang, Lars Palmqvist, Anna Sjöblom-Hallén, Lars Rymo.   

Abstract

The Epstein-Barr virus (EBV) tumor-associated latent membrane protein 1 (LMP1) gene expression is transactivated by EBV nuclear antigen 2 (EBNA2) in human B cells. We previously reported that an E-box element at the LMP1 regulatory sequence (LRS) represses transcription of the LMP1 gene through the recruitment of a Max-Mad1-mSin3A complex. In the present study, using deletion/mutation analysis, and electrophoretic mobility shift assays, we show that the promoter region adjacent to the E-box (-59/-67) is required for the full repression conferred by E-box binding proteins. The repressive effect of these factors was overcome by an inhibitor of histone deacetylation, Trichostatin A (TSA), concurring with the reports that histone deacetylation plays an important role in repression mediated by Max-Mad1-mSin3A complex. Furthermore, ChIP analyses showed that histones at the transcriptionally active LMP1 promoter were hyperacetylated, whereas in the absence of transcription they were hypoacetylated. EBNA2 activation of the promoter required a consensus AP-2 sequence in the -103/-95 LRS region. While EMSA results and the low level of AP-2 factors expression in B cells argue against known AP-2 factors binding to this site, several pieces of evidence point to a similar mechanism of promoter activation as seen by AP-2 factors. We conclude that an AP-2 site-binding factor and EBNA2 act in concert to overcome the repression of the LMP1 promoter via the consensus AP-2 site. This activation showed strong correlation with histone hyperacetylation at the promoter, indicating this to be a major mechanism for the EBNA2 mediated LMP1 transactivation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17546492     DOI: 10.1007/s11262-007-0116-x

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  50 in total

1.  A role for SKIP in EBNA2 activation of CBF1-repressed promoters.

Authors:  S Zhou; M Fujimuro; J J Hsieh; L Chen; S D Hayward
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

Review 2.  CBP/p300 in cell growth, transformation, and development.

Authors:  R H Goodman; S Smolik
Journal:  Genes Dev       Date:  2000-07-01       Impact factor: 11.361

3.  Domains of the Epstein-Barr virus nuclear antigen 2 (EBNA2) involved in the transactivation of the latent membrane protein 1 and the EBNA Cp promoters.

Authors:  A Sjöblom; A Nerstedt; A Jansson; L Rymo
Journal:  J Gen Virol       Date:  1995-11       Impact factor: 3.891

4.  Sensitivity of Epstein-Barr virus (EBV) producer and non-producer human lymphoblastoid cell lines to superinfection with EB-virus.

Authors:  G Klein; L Dombos; B Gothoskar
Journal:  Int J Cancer       Date:  1972-07-15       Impact factor: 7.396

5.  A family of AP-2 proteins regulates c-erbB-2 expression in mammary carcinoma.

Authors:  J M Bosher; N F Totty; J J Hsuan; T Williams; H C Hurst
Journal:  Oncogene       Date:  1996-10-17       Impact factor: 9.867

6.  The Epstein-Barr virus 3.5-kilobase latent membrane protein 1 mRNA initiates from a TATA-Less promoter within the first terminal repeat.

Authors:  R H Sadler; N Raab-Traub
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

7.  The Epstein-Barr virus nuclear protein 2 acidic domain can interact with TFIIB, TAF40, and RPA70 but not with TATA-binding protein.

Authors:  X Tong; F Wang; C J Thut; E Kieff
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

8.  Epstein-Barr virus nuclear protein 2 (EBNA2) binds to a component of the human SNF-SWI complex, hSNF5/Ini1.

Authors:  D Y Wu; G V Kalpana; S P Goff; W H Schubach
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

9.  The 5' flanking region of the gene for the Epstein-Barr virus-encoded nuclear antigen 2 contains a cell type specific cis-acting regulatory element that activates transcription in transfected B-cells.

Authors:  A Ricksten; A Olsson; T Andersson; L Rymo
Journal:  Nucleic Acids Res       Date:  1988-09-12       Impact factor: 16.971

10.  Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes.

Authors:  W Hammerschmidt; B Sugden
Journal:  Nature       Date:  1989-08-03       Impact factor: 49.962

View more
  9 in total

1.  The LMP1 promoter can be transactivated directly by NF-kappaB.

Authors:  Constantinos Demetriades; George Mosialos
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

2.  Nuclear factor-kappaB binds to the Epstein-Barr Virus LMP1 promoter and upregulates its expression.

Authors:  Pegah Johansson; Ann Jansson; Ulla Rüetschi; Lars Rymo
Journal:  J Virol       Date:  2008-11-19       Impact factor: 5.103

3.  The p38 signaling pathway upregulates expression of the Epstein-Barr virus LMP1 oncogene.

Authors:  Pegah Johansson; Ann Jansson; Ulla Rüetschi; Lars Rymo
Journal:  J Virol       Date:  2010-01-06       Impact factor: 5.103

4.  Differential gene regulation by Epstein-Barr virus type 1 and type 2 EBNA2.

Authors:  Walter Lucchesi; Gareth Brady; Oliver Dittrich-Breiholz; Michael Kracht; Rainer Russ; Paul J Farrell
Journal:  J Virol       Date:  2008-05-14       Impact factor: 5.103

5.  Induction of Epstein-Barr Virus Oncoprotein LMP1 by Transcription Factors AP-2 and Early B Cell Factor.

Authors:  Takayuki Murata; Chieko Noda; Yohei Narita; Takahiro Watanabe; Masahiro Yoshida; Keiji Ashio; Yoshitaka Sato; Fumi Goshima; Teru Kanda; Hironori Yoshiyama; Tatsuya Tsurumi; Hiroshi Kimura
Journal:  J Virol       Date:  2016-03-28       Impact factor: 5.103

6.  C-terminal region of EBNA-2 determines the superior transforming ability of type 1 Epstein-Barr virus by enhanced gene regulation of LMP-1 and CXCR7.

Authors:  Laila Cancian; Rachel Bosshard; Walter Lucchesi; Claudio Elgueta Karstegl; Paul J Farrell
Journal:  PLoS Pathog       Date:  2011-07-28       Impact factor: 6.823

Review 7.  Mutations in components of antiviral or microbial defense as a basis for breast cancer.

Authors:  Bernard Friedenson
Journal:  Funct Integr Genomics       Date:  2013-09-21       Impact factor: 3.674

Review 8.  Burkitt's lymphoma: the Rosetta Stone deciphering Epstein-Barr virus biology.

Authors:  Martin Rowe; Gemma L Kelly; Andrew I Bell; Alan B Rickinson
Journal:  Semin Cancer Biol       Date:  2009-07-18       Impact factor: 15.707

9.  Characterization of a Suppressive Cis-acting Element in the Epstein-Barr Virus LMP1 Promoter.

Authors:  Masahiro Yoshida; Takayuki Murata; Keiji Ashio; Yohei Narita; Takahiro Watanabe; H M Abdullah Al Masud; Yoshitaka Sato; Fumi Goshima; Hiroshi Kimura
Journal:  Front Microbiol       Date:  2017-11-22       Impact factor: 5.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.